Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximab

Schopf, R. E.; Aust, Holger; Knop, Jürgen

doi:10.1067/mjd.2002.120472

Cited by 99 publications

(66 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…En otro trabajo similar, Schopf y cols 6 , que trataron a 8 pacientes con psoriasis moderada a severa, con infliximab 5 mg/kg/dosis iv en la semana 0, 2 y 6. Observaron que 87,5% de los pacientes /7 de 8) presentaron un descenso del PASI ≥75% del PASI basal a la semana 10.…”

Section: Discussionunclassified

Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)

A¹,

et al. 2006

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

Section: Discussionunclassified

Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)

A¹,

et al. 2006

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

“…In Crohn's disease the preferred regimen consists of a single 5mglkg infusion which can be repeated after 2 and 6 weeks in case of unsatisfactory response. The use of infliximab, either in monotherapy or in combination with methotrexate, has also been investigated in other immune-mediated diseases, especially psoriasis and psoriatic arthritis (15)(16)(17)(18)(19)(20)(21). Ever-increasing evidence has shown the dramatic and prompt response to infliximab monotherapy in patients with moderate to severe recalcitrant psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Infliximab Monotherapy for Refractory Psoriasis: Preliminary Results

Cassano

Loconsole

Аморусо

et al. 2004

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Tumour necrosis factor (TNF)-alpha plays an important role in the pathogenesis of psoriasis. Infliximab is an anti-TNF-alpha chimeric monoclonal antibody, which is licensed for the treatment of rheumatoid arthritis and Crohn's disease. Some reports have shown the efficacy of infliximab, either in monotherapy or in combination with methotrexate, for the treatment of psoriatic arthropathy and psoriasis. The efficacy and tolerability of infliximab monotherapy was evaluated in 29 patients with moderate to severe psoriasis, unresponsive to conventional treatments. Fourteen patients suffered from concomitant arthropathy. Patients received intravenous infliximab, 5mg/kg, at weeks 0, 2, and 6. After this 3-dose-induction regimen, patients were followed-up at monthly intervals and retreated with a single-dose infusion in case of relapse of signs and symptoms. Clinical assessment was performed using the psoriasis area and severity index (PASI) to monitor psoriasis activity; pruritus and joint pain were assessed on a scale of 0 to 3. A marked improvement of skin lesions and subjective symptoms was noted in the majority of patients; an excellent reduction of PASI score (⩾75%) was observed in 13.8% of cases at week 2, 71.4% at week 6 and 78.6% at week 10. During the follow-up period, some patients maintained satisfactory clinical results without requiring any additional infusions. In general, skin lesions showed a trend towards a more prolonged and sustained improvement as compared with subjective symptoms. Treatment was well tolerated and no serious adverse events occurred.

show abstract

“…The emergence of tumor necrosis factor inhibitor therapy for psoriasis occurred during this period, sparking a series of clinical trials that showed remarkable clinical outcomes and changed the way dermatologists manage psoriasis. [13][14][15] Furthermore, with advancements in DNA technology, publications that analyzed the genetics of psoriasis grew quickly. Last, although the association of psoriasis with cardiovascular disease had been speculated on for some time, the topic received increased attention in recent years.…”

Section: Discussionmentioning

confidence: 99%

Trends in Type of Original Psoriasis Publications by Decade, 1960 to 2010

Sako

Famenini

2016

TPJ

View full text Add to dashboard Cite

Context:Research investigating psoriasis has spanned decades, and as our understanding of the disease has evolved, the focus of publications has changed.Objective: We sought to characterize the trends in original psoriasis-related research from 1960 to 2010 chronologically by decade.Methods: A literature review was performed using the keyword psoriasis in the MED-LINE database. All original psoriasis-related articles published at the beginning of each decade were searched and categorized by study type and topic.Main Outcome Measure: Number of articles per topic.Results: A total of 869 original psoriasis-related articles were found. The number of publications increased 18 fold over 5 decades. The immunology and pathogenesis of psoriasis was the most frequently researched topic (36%), and retrospective studies were the most common study type (37%). Recent highly published topics included biologic therapy, genetics, and psoriasis-associated cardiovascular disease.Conclusion: Original psoriasis-related publications have grown substantially since 1960. Basic science research into the immunology and pathogenesis has been and continues to be the mainstay of psoriasis research. Recent research trends suggest the focus has expanded to topics such as psoriasis-associated cardiovascular disease, genetics, and biologic therapy. INTRODUCTIONPsoriasis is a chronic inflammatory skin condition affecting 2% of the population, and it can be physically and psychologically debilitating.1 Although psoriasis was first described in 1841, it was the 1960s that first saw a surge in psoriasis-related research. Initial studies focused on the keratinocyte, and nonmalignant proliferation and reduced differentiation were found to be hallmarks of psoriasis. Since then, considerable achievements have changed the way psoriasis is viewed. Advances in technology have allowed researchers to gain an understanding of the molecular mechanisms driving the disease. Breakthroughs in biologic therapy have revolutionized the way psoriasis is managed. Recent research suggests that patients with psoriasis have a systemic inflammatory state, putting them at increased risk of cardiovascular complications, including metabolic syndrome, peripheral vascular disease, stroke, myocardial infarction, and cardiac death.3,4 Some articles suggest that tumor necrosis factor inhibitors may decrease the risk of stroke and myocardial infarction in patients with psoriasis. 5,6 As understanding of the disease has continued to evolve over five decades, research interests have expanded. Our goal is to identify these new components to gain a better understanding of the current landscape and future direction of psoriasis-related research. On the basis of recent study findings, we hypothesized that there would be a higher proportion of recent publications investigating psoriasis-associated cardiovascular disease and biologic therapy. To our knowledge, no study has systematically examined research trends in this field. We sought to accomplish this through a literature rev...

show abstract

Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α, infliximab

Cited by 99 publications

References 20 publications

Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)

Eficacia y seguimiento en el largo plazo de pacientes con psoriasis vulgar moderada a severa en tratamiento con infliximab (Remicade®)

Infliximab Monotherapy for Refractory Psoriasis: Preliminary Results

Trends in Type of Original Psoriasis Publications by Decade, 1960 to 2010

Contact Info

Product

Resources

About